Syndax Pharmaceuticals Inc (SNDX) reports promising revenue from Revv Forge launch and outlines strategic growth plans, ...

HC Wainwright restated their buy rating on shares of Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) in a report published ...

Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a ...

About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® ...

Barclays analyst Peter Lawson maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report) yesterday and set a price target of ...

Highlights,Target price adjustments for Syndax Pharmaceuticals reflect varied market sentiment.,Executive decisions on stock ...

Investing.com – U.S. stocks were lower after the close on Tuesday, as losses in the Healthcare, Technology and Consumer Services sectors led shares lower. At the close in NYSE,... Top Gainers ...

NEW YORK, March 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today ...

After hours: March 7 at 6:38:22 p.m. EST Loading Chart for SNDX ...

After hours: March 7 at 6:38:22 p.m. EST ...

A few days after a disappointing clinical trial readout for Syndax Pharma's Revuforj in one form of leukaemia, the company has claimed FDA approval in another. The US regulator has cleared oral ...